Dianthus Therapeutics (DNTH) Return on Sales (2022 - 2025)

Dianthus Therapeutics' Return on Sales history runs 4 years deep, the most recent figure standing at 4.17% for Q3 2025.

• On a quarterly basis, Return on Sales fell 383.0% year-over-year to 4.17% in Q3 2025; TTM through Sep 2025 was 0.92%, a 60.0% decrease from a year earlier, with the FY2024 full-year figure at 0.43%, up 18.0% from the prior year.
• Return on Sales retreated to 4.17% in Q3 2025 per DNTH's latest filing, from 2.62% in the prior quarter.
• Across five years, Return on Sales topped out at 0.09% in Q4 2022 and bottomed at 4.17% in Q3 2025.
• The 4-year median for Return on Sales is 0.24% (2023), against an average of 0.72%.
• Across the five-year window, Return on Sales climbed 15 bps in 2024 and slumped 383 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.09% in 2022, then plunged by 285 bps to 0.33% in 2023, then surged by 44 bps to 0.18% in 2024, then sank by 2172 bps to 4.17% in 2025.
• Per Business Quant, the three latest DNTH Return on Sales figures stand at 4.17% (Q3 2025), 2.62% (Q2 2025), and 0.39% (Q1 2025).